Before the conversation gets underway, three sponsors get their moment. Odoo pitches itself as the antidote to the fragmented, multi-app software stack that plagues growing businesses — one platform for accounting, sales, inventory, and marketing. Section follows, with Scott Galloway offering an unusually candid aside: this is a paid ad, he says, but also a genuine conviction — he's an investor in Section because he believes the most underinvested layer of the AI economy is helping employees actually use the tools. Section counts Nike, Autodesk, and NASCAR among its clients. Finally, Northwest Registered Agent rounds out the block, emphasizing business privacy and a free foundation layer for entrepreneurs. The sequence sets up a podcast that blends commercial interests with intellectual candor.

In his intro monologue, Scott Galloway marks the show's 399th episode with characteristic wit — invoking the world's most photographed grizzly bear and a joke from The Sopranos — before pivoting to the substance. He makes his starkest contrarian claim: GLP-1 drugs are the most underhyped technology of the decade, more transformative than AI, which he considers the most overhyped. He has named GLP-1s his 'technology of the year' for two consecutive years in his annual predictions deck. His framing — that these drugs are 'scaffolding on our instincts,' compensating for biology that hasn't kept pace with industrial food production — sets the intellectual tone for everything that follows. The guest: David Ricks, Chair and CEO of Eli Lilly, the first healthcare company to reach a trillion-dollar valuation.

Ricks opens with a story that feels almost mythic in a modern context: Eli Lilly was the fifth company its founder tried to start — the first four failed. A Civil War colonel who witnessed the horrors of battlefield infections and negligent medical care, he resolved to do something new. His first act was radical for 1876: list every ingredient on every medicine bottle, then sign it himself. His first hire was a scientist. This founding commitment to transparency and quality predated the FDA by decades and planted the seed of what Lilly would become. Ricks notes that every product the company has ever made eventually goes off-patent and drops to zero — forcing a culture of perpetual reinvention. GLP-1s, he suggests, are simply the latest chapter in that long story.

Most chronic disease drugs, Ricks explains, work for some people and not others — and patients typically feel worse taking them. GLP-1s break this pattern on both counts: nearly universal efficacy and a subjective experience patients actually welcome. That's unusual. Add the fact that obesity connects causally to more than 200 chronic diseases — from diabetes and cardiovascular disease to inflammation and cancer — and you have what Ricks calls a 'nodal' health condition. Fix obesity at scale and you potentially pull down a cascade of downstream costs and suffering. Galloway layers in the macro: US healthcare costs $13,500 per person versus Japan's $5,500, and the countries' obesity rates differ by roughly 36 percentage points. His thesis: you cannot address the US fiscal deficit without addressing healthcare, and you cannot address healthcare without addressing obesity. Ricks largely agrees.

What began as a diabetes drug keeps revealing new capabilities. Ricks walks through the cascade: inflammation reduction (GLP-1s appear to be powerful anti-inflammatories, relevant to arthritis, asthma, psoriasis), and then the stranger, harder-to-explain behavioral effects. Patients in trials spontaneously drank less alcohol, gambled less, and shopped less online — without being asked or prompted. The mechanism, Ricks theorizes, is that alcohol is chemically close to glucose, and the same brain signaling that reduces sugar cravings quiets alcohol desire too. Critically, he pushes back on the 'joy kill switch' narrative: people don't lose pleasure, they just find less appetite for excess. Lilly is now running Phase 3 trials on brenepatide for alcohol use disorder. On pain: retatrutide, the triple-acting drug expected to launch next year, showed the most powerful knee pain reduction ever recorded pharmacologically — a finding with enormous implications given the scale of chronic pain in America. Cancer connections remain observational but are striking: people on GLP-1s for 5–6 years appear to have lower rates of colorectal and breast cancer.

The pricing question is the sharpest edge of the conversation. Galloway frames it as a contradiction: Lilly has a fiduciary duty to shareholders to maintain pricing power, but the people who need these drugs most — lower-income, obese Americans — are least likely to afford them. Ricks reframes the economics: unlike most specialty drugs where demand is inelastic, GLP-1 demand is highly elastic — drop the price and volume surges. So lowering the price actually serves shareholders, not just patients. He details LillyDirect, a direct-to-consumer channel that bypasses pharmacy benefit managers and lets individuals buy at institutional prices — Zepbound is now $399/month, down 60% since launch. The new oral drug Foundeo starts at $159. Ricks then describes the Mississippi Medicaid deal — a state where 78–79% of adults are obese and Medicaid enrollment is the nation's highest — as a proof point of what systemic change can look like. And starting July 1, all 70 million Medicare seniors can access Lilly's obesity drug for $50/month. The final challenge: trust. Because pharma has historically been extractive on pricing, Ricks admits there's a genuine trust gap to overcome.

The episode pauses for a commercial break covering website-building, digital privacy, and recruiting. Framer pitches its visual canvas as the gap-closer between AI-generated ideas and production-ready websites, with a 30% discount on Pro annual plans. Proton VPN leads with the surveillance economy pitch — the moment you Google something, ads follow — and offers 70% off a two-year plan. LinkedIn closes the block by promoting Hiring Pro, citing its own data that nearly 60% of small business hires find someone to interview within a week.

Scott Galloway asks for a plain-English explainer on peptides — a word now everywhere in wellness culture. Ricks obliges with a short biochemistry lesson: a peptide is simply a chain of amino acids, a foundational term in biology, and the fact that online marketing has made it sound exotic says more about modern commerce than science. His critique of the unregulated peptide market is pointed: these are 'unstudied medicines,' substances sold without clinical trials, safety data, or any third-party verification of what's actually in them. Some mimic growth hormone — which is also pro-tumor growth, Ricks notes drily. But the more revealing part of his answer is the sociological diagnosis: the peptide boom is a symptom of a genuinely broken consumer healthcare experience. No prices, long waits, condescension, information asymmetry — all of it has driven people to take agency online, armed with N-of-1 anecdotes and biochemistry they can't verify. 'That's not science,' Ricks says, but he acknowledges the underlying frustration is legitimate. The healthcare system has earned some of the distrust now being directed at it.

Galloway frames the question bluntly: Lilly's stock is up fivefold in five years and is worth more than J&J, Pfizer, and Merck combined. What's the secret? Ricks identifies three factors. First, capital allocation: Lilly committed to GLP-1s in 2018, when the obesity drug market was considered a non-market — the bad history of fen-phen and earlier failures had scared everyone off. Lilly bet anyway because the biology was compelling. Second, speed: when Ricks became CEO, it took Lilly 11 years from invention to market — longer than the remaining patent life of the drug. They've since cut that by five years, giving them a decisive edge over rivals who haven't. Third, culture: Lilly has never had a major merger, is based in Indianapolis rather than a biotech hub, has fewer than 50,000 employees, and maintains a Midwest nice ethos where senior leaders know each other and can solve problems without committee meetings. Ricks frames the overall philosophy as going where others won't: 'By the time a medicine market is big, it's basically too late to invest.'

Jensen Huang's vision of AI as the engine of a 'great age of discovery' in biotech gets a reality check from the CEO of the world's most valuable pharma company. Ricks is not dismissive — Lilly scientists use OpenAI and Anthropic tools daily and he's working with NVIDIA to build better biological datasets. But he draws a sharp distinction: LLMs excel at synthesizing the totality of human written knowledge, and they're good at it because that knowledge base is nearly complete. Biology isn't. Humans have mapped perhaps 10–20% of how the human body actually works, which means training an AI on it produces models that are 'terrible at predicting' outcomes in the remaining 80%. The second limitation: drug discovery ultimately requires physical experimentation. Tirzepatide was the 700th formulation tested — and the 20 of roughly 1,000 preclinical steps that Lilly has automated with AI or machine learning still leave 980 to go. The human experimentation phase — clinical trials — can't be shortcut by AI for the foreseeable future. His estimate: five to seven years before AI meaningfully reduces laboratory experiments, and a full ten-year arc before it genuinely accelerates drug discovery at scale.

Rippling leads with its pitch for AI that doesn't just surface insights but acts on them — generating retention strategies and executing spot bonuses directly from workforce data. The BetterHelp segment takes a data-forward approach, citing its 2026 State of Stigma report: 85% of Americans believe getting support is a smart thing to do, yet 74% say society discourages it. More than three in four Americans reported anxiety or depression symptoms in the past two weeks. The segment closes with a memorable line: 'Maybe it's time to close a few tabs.'

Galloway pivots to the human dimension — asking what Ricks would tell his 25-year-old self. The answer is characteristically direct: say yes to the things that scare you. Ricks stumbled into pharma because his future wife was in medical school in Indianapolis — he just needed a nearby job. He later moved his family to China to run Lilly's operations there, with his physician wife giving up her career to do so. He doesn't romanticize the sacrifice, but he says those decisions shaped everything. His second piece of advice cuts against the grain of modern career culture: stay somewhere long enough to actually understand it. Genuine mastery of a complex industry takes 15 years, he argues — job-hopping optimizes for salary but not knowledge. On raising sons, Ricks is both self-critical and wise: he was too demanding, too impatient with a developmental process that, for men, doesn't fully complete until the mid-20s. The most resonant observation: men connect side by side, not face to face. Hiking, camping, walking — these create the conditions for real conversation with teenage boys better than organized sports spectatorship. The death of his father last year has made him more intentional. He's scheduled a trip to Europe with his oldest son this summer.

Galloway wraps the substantive conversation with a brief lightning round that reveals the human behind the CEO. Guilty pleasure: a good meal. Last media habit: scrolling X on weekends for biotech news from the cancer conference (with some political junk, he admits). Salad days: 'I hope that's ahead of me,' though right now — kids out of the house, wife no longer working, more time together — is pretty good. Biggest life influence: his father, who passed away last year. That loss, he says, has reoriented him toward creating intentional one-on-one moments with his sons — the kind of memories he now treasures with his own father. Galloway signs off by celebrating what he calls 'a great American story': the world's most valuable biotech company, headquartered not in Silicon Valley or London, but in Indianapolis, Indiana.

Fetch Pet Insurance leads with a striking statistic: every 6 seconds a pet owner in the US gets hit with a vet bill over $1,000. Their pitch is comprehensive coverage at up to 90% reimbursement at any US or Canadian vet. Mint Mobile closes the episode with Ryan Reynolds' signature deadpan humor — he wanted to print $15 bills to illustrate Mint's price point, but that turns out to be a federal crime. The offer: unlimited premium wireless at $15/month, with the standard fine print on payment structure and data throttling after 50 gigabytes.